Melasma is a chronic pigmentation disorder that produces brown or grey-brown patches on the face — forehead, cheeks, upper lip, and nose. It is caused by overactive melanocytes producing excess melanin in response to three main triggers: UV radiation, hormonal changes (pregnancy, contraceptives, PCOD), and heat.
In Indian skin (Fitzpatrick III–V), these melanocytes are naturally more active and more easily triggered than in lighter skin types. Kota's high UV exposure year-round means even brief unprotected sun exposure continuously reactivates the melanocyte activity that treatment is trying to suppress. This is the primary reason melasma in Kota patients is more persistent than in patients in lower-UV environments — the trigger is almost always present unless sunscreen is applied consistently.
Melasma also deposits at two depths — the epidermis (surface layer) and the dermis (deeper layer). Epidermal melasma responds reasonably well to topical agents. Dermal melasma does not respond to creams at all — it requires laser or device-based treatment to reach. Most patients presenting with long-standing melasma have both components, which is why creams alone plateau after initial improvement.
Hydroquinone, kojic acid, azelaic acid, retinoids, and tranexamic acid are all clinically effective for epidermal melasma. They work by suppressing tyrosinase activity (the enzyme that drives melanin production) at the skin surface. The limitation:
This is not a failure of the creams — it is the correct boundary of what they can achieve. The next step is adding device-based treatment to address what topical agents cannot reach.
| Treatment component | Depth it addresses | What it achieves | Standalone limitation |
|---|---|---|---|
| Topical agents (retinoid, azelaic acid, tranexamic acid) | Epidermal | Suppresses tyrosinase, reduces surface melanin production | Cannot reach dermal deposits; requires continuous use |
| Chemical peel (glycolic, TCA, combination) | Epidermal to superficial dermal | Exfoliates pigmented surface layers; accelerates cell turnover | Risk of post-peel hyperpigmentation in Indian skin without preparation |
| Q-Switch Nd:YAG laser toning | Epidermal and dermal | Fragments melanin deposits at both depths; reduces melanocyte overactivity | Melanin reactivates between sessions without internal suppression |
| Glutathione IV therapy | Systemic (cellular level) | Suppresses melanin synthesis from within; reduces reactivation rate between laser/peel sessions | Gradual on its own; most effective when combined with peel or laser |
The combination plan addresses melasma at all three levels simultaneously — surface suppression, existing deposit removal, and internal melanin reactivation prevention. This is why patients on a correctly designed combination course at Skinssence see visible improvement within 4–6 sessions when months of topical-only treatment produced only partial, reversible improvement.
No melasma treatment — laser, peel, or prescription cream — can produce lasting improvement without daily broad-spectrum sunscreen. In Kota's UV environment, melanocytes are continuously stimulated by UV exposure. Every session of laser toning or chemical peel that goes unprotected by sunscreen is partially reversed by the UV exposure that follows it.
SPF 30+ broad-spectrum sunscreen applied every morning — including overcast days and during indoor work near windows — is the single most important component of any melasma treatment plan. Patients who maintain consistent sunscreen use sustain their results significantly longer between maintenance sessions than those who use sunscreen inconsistently. See the full sun protection guide →
Recurrence almost always has one of three causes: insufficient sun protection allowing UV to continuously retrigger melanocyte activity, stopping treatment before the full course is complete, or using only topical agents without addressing the dermal component. A combination plan with laser toning, peel, glutathione IV, and consistent sunscreen produces significantly more durable results. See the full melasma treatment page →
Q-Switch Nd:YAG laser toning is safe for Indian skin (Fitzpatrick III–V) when performed at conservative settings by a dermatologist who calibrates parameters for your specific skin tone. The risk in Indian skin is post-inflammatory hyperpigmentation from aggressive settings — this is prevented by correct parameter selection, pre-treatment preparation, and post-treatment sun protection. Laser applied to active melasma without preparation can worsen the condition — which is why clinical assessment precedes any laser session at Skinssence.
Most patients on a combination plan (laser toning + chemical peel + glutathione IV) see visible improvement by sessions 4–6. A full course of 6–10 sessions produces the clearest result. The exact number depends on melasma depth, duration, skin tone, and sunscreen compliance. Maintenance sessions every 1–2 months after the initial course sustain the improvement.
Yes — with the understanding that hormonal pigmentation driven by PCOD requires both the cosmetic treatment (laser, peel) and the hormonal management to be addressed simultaneously. Treating only the surface pigmentation while the hormonal trigger continues is a cycle of partial improvement and relapse. See PCOD treatment at Skinssence →
Most corrective treatments — laser, TCA peels, combination peels, retinoids — are restricted during pregnancy and breastfeeding. The most effective intervention during pregnancy is daily mineral sunscreen to prevent UV from amplifying the hormonal pigmentation. Corrective treatment begins after breastfeeding ends. Starting treatment within 6–12 months of delivery while pigmentation is relatively recent produces the best outcomes.
Related: Melasma and pigmentation treatment at Skinssence → · Laser skin toning in Kota → · Chemical peels → · Glutathione IV drip → · Pigmentation and brightening guide →